Page last updated: 2024-08-23

pizotyline and Akinetic-Rigid Variant of Huntington Disease

pizotyline has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ellerby, LM; Hughes, RE; Papanikolaou, T; Sarantos, MR	1

Other Studies

1 other study(ies) available for pizotyline and Akinetic-Rigid Variant of Huntington Disease

Article	Year
Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease. Journal of Huntington's disease, 2012, Volume: 1, Issue:2 Topics: Animals; Apoptosis; Cells, Cultured; Corpus Striatum; Dose-Response Relationship, Drug; Huntington Disease; MAP Kinase Signaling System; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Pizotyline; Treatment Outcome	2012

Article

Year

Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.

Journal of Huntington's disease, 2012, Volume: 1, Issue:2

Topics: Animals; Apoptosis; Cells, Cultured; Corpus Striatum; Dose-Response Relationship, Drug; Huntington Disease; MAP Kinase Signaling System; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Pizotyline; Treatment Outcome

2012